HC Wainwright Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price

Immunic (NASDAQ:IMUX) had its price objective decreased by analysts at HC Wainwright from $8.00 to $5.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 390.20% from the company’s current price.

A number of other research firms have also weighed in on IMUX. D. Boral Capital decreased their target price on shares of Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Chardan Capital upgraded Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. Roth Mkm began coverage on Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 price objective for the company. Brookline Capital Acquisition upgraded Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $6.00.

Immunic Stock Performance

NASDAQ:IMUX opened at $1.02 on Monday. The business’s fifty day moving average is $0.70 and its 200 day moving average is $0.76. The firm has a market cap of $133.07 million, a price-to-earnings ratio of -1.46 and a beta of 1.45. Immunic has a 52-week low of $0.51 and a 52-week high of $1.35.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

Large investors have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd bought a new stake in Immunic during the third quarter worth about $29,000. Two Sigma Investments LP purchased a new position in shares of Immunic during the 3rd quarter valued at about $52,000. HB Wealth Management LLC bought a new stake in Immunic in the 3rd quarter worth approximately $81,000. Seven Fleet Capital Management LP bought a new stake in Immunic in the 4th quarter worth approximately $83,000. Finally, Virtu Financial LLC purchased a new stake in Immunic in the third quarter worth approximately $99,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.